{"protocolSection":{"identificationModule":{"nctId":"NCT04716933","orgStudyIdInfo":{"id":"7902-006 China Extension"},"secondaryIdInfos":[{"id":"MK-7902-006","type":"OTHER","domain":"Merck"},{"id":"E7080-G000-315","type":"OTHER","domain":"Eisai Protocol Number"},{"id":"LEAP-006","type":"OTHER","domain":"MSD"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study","officialTitle":"A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)"},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-11-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-08-11","type":"ACTUAL"},"completionDateStruct":{"date":"2024-08-30","type":"ACTUAL"},"studyFirstSubmitDate":"2021-01-19","studyFirstSubmitQcDate":"2021-01-19","studyFirstPostDateStruct":{"date":"2021-01-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-07-30","resultsFirstSubmitQcDate":"2024-09-19","resultsFirstPostDateStruct":{"date":"2024-10-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-08-20","lastUpdatePostDateStruct":{"date":"2025-09-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"collaborators":[{"name":"Eisai Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with metastatic nonsquamous non-small cell lung cancer.\n\nThe primary study hypotheses state that: 1) the combination of lenvatinib+platinum doublet chemotherapy+pembrolizumab prolongs Progression-free Survival (PFS) as assessed by blinded independent central review (BICR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST 1.1) compared to matching placebo+platinum doublet chemotherapy+pembrolizumab, and 2) the combination of lenvatinib+platinum doublet chemotherapy+pembrolizumab prolongs Overall Survival (OS) compared to matching placebo+platinum doublet chemotherapy + pembrolizumab.","detailedDescription":"The China extension study will include participants previously enrolled in mainland China for the global study for MK-7902-006 (NCT03829319) plus those enrolled in mainland China as part of the China extension enrollment period."},"conditionsModule":{"conditions":["Nonsquamous Non-small Cell Lung Cancer"],"keywords":["programmed cell death 1 (PD-1, PD1)","programmed cell death-ligand 1 (PD-L1, PDL1)","programmed cell death-ligand 2 (PD-L2, PDL2)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":201,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","type":"EXPERIMENTAL","description":"Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily.","interventionNames":["Biological: Pembrolizumab","Drug: Carboplatin","Drug: Cisplatin","Drug: Pemetrexed","Drug: Lenvatinib"]},{"label":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","type":"PLACEBO_COMPARATOR","description":"Participants receive carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily.","interventionNames":["Biological: Pembrolizumab","Drug: Carboplatin","Drug: Cisplatin","Drug: Pemetrexed","Drug: Placebo matching lenvatinib"]}],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","description":"IV infusion Q3W","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"],"otherNames":["MK-3475"]},{"type":"DRUG","name":"Carboplatin","description":"IV infusion Q3W","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"]},{"type":"DRUG","name":"Cisplatin","description":"IV infusion Q3W","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"]},{"type":"DRUG","name":"Pemetrexed","description":"IV infusion Q3W","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"]},{"type":"DRUG","name":"Lenvatinib","description":"Oral capsule once daily","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib"],"otherNames":["MK-7902","E7080"]},{"type":"DRUG","name":"Placebo matching lenvatinib","description":"Oral capsule once daily","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 is presented.","timeFrame":"Up to approximately 43 months"},{"measure":"Part 2: Overall Survival (OS)","description":"OS is defined as the time from randomization to the time of death from any cause. OS is presented.","timeFrame":"Up to approximately 43 months"}],"secondaryOutcomes":[{"measure":"Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR as assessed per modified RECIST 1.1 will be presented.","timeFrame":"Up to approximately 57 months"},{"measure":"Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. DOR as assessed per modified RECIST 1.1 will be presented.","timeFrame":"Up to approximately 57 months"},{"measure":"Part 2: Number of Participants Who Experienced an Adverse Event (AE)","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one of more adverse events during Part 2 of this study were presented.","timeFrame":"Up to approximately 42 months"},{"measure":"Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment during Part 2 of this study were presented.","timeFrame":"Up to approximately 42 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of Stage IV (American Joint Committee on Cancer \\[AJCC\\], version 8 or current version) nonsquamous NSCLC.\n* Confirmation that Epidermal Growth Factor Receptor (EGFR), ALK Receptor Tyrosine Kinase (ALK), or ROS1 Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated as primary treatment (documentation of absence of tumor-activating EGFR mutations AND absence of ALK and ROS1 gene rearrangements OR presence of a Kirsten Rat Sarcoma (KRAS) gene mutation).\n* Have measurable disease based on RECIST 1.1. Note: Lesions that appear measurable, but are situated in a previously irradiated area, can be considered measurable (eligible for selection as target lesions) if they have shown documented growth since the completion of radiation.\n* Provided an evaluable archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (that was not previously irradiated) for central PD-L1 testing.\n* Life expectancy of at least 3 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study intervention but before randomization.\n* Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and/or lenvatinib/matching placebo and up to 180 days after the last dose of chemotherapeutic agents. A male participant must also agree to the following: 1) abstinence from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, OR 2) agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant, unless confirmed to be azoospermic (vasectomized or secondary to medical cause). Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.\n* Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) not a WOCBP OR 2) a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention.\n* Adequate organ function.\n* Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week prior to randomization. Note: Participants must not have a history of uncontrolled or poorly-controlled hypertension, defined as \\>150/90 mm Hg for \\>4 weeks despite standard medical management.\n\nExclusion Criteria:\n\n* Known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable, and have not required steroids for at least 14 days prior to the first dose of study intervention.\n* History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.\n* Radiographic evidence of major blood vessel invasion/infiltration.\n* Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy. Note: The time requirement also does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.\n* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.\n* Has had allogeneic tissue/solid organ transplant.\n* Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.\n* Known history of Hepatitis B or active Hepatitis C. No testing for Hepatitis B or Hepatitis C is required unless mandated by the local health authority.\n* History of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral drug absorption.\n* Active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention.\n* Significant cardiovascular impairment within 12 months prior to the first dose of study intervention, including history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, cerebrovascular accident (CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability.\n* Known history of active tuberculosis.\n* Active infection requiring systemic therapy.\n* Has not recovered adequately from any toxicity and/or complication from major surgery prior to the first dose of study intervention.\n* Previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of lenvatinib or pembrolizumab, or as applicable, carboplatin, cisplatin, or pemetrexed.\n* Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and/or lenvatinib/matching placebo and up to 180 days after last dose of chemotherapeutic agents.\n* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC.\n* Received prior treatment with pembrolizumab or any other anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent, with lenvatinib or any other receptor tyrosine kinase inhibitor (RTKi), or with an agent directed to another stimulatory or co-inhibitory T cell receptor.\n* Received radiotherapy within 14 days prior to the first dose of study intervention or received lung radiation therapy of \\>30 Gy within 6 months prior to the first dose of study intervention. Note: Participants must have recovered from all radiation-related toxicities to Grade ≤1, not required corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.\n* Received systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study intervention.\n* Received a live vaccine within 30 days prior to the first dose of study intervention.\n* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention.\n* Has a prolongation of QTc interval (calculated using Fridericia's formula) of \\>480 msec\n* Left ventricular ejection fraction (LVEF) below the institutional (or local laboratory) normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).\n* Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Peking Union Medical College Hospital ( Site 0108)","city":"Beijing","state":"Beijing Municipality","zip":"100006","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Cancer Hospital Chinese Academy of Medical Science ( Site 0117)","city":"Beijing","state":"Beijing Municipality","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Cancer Hospital ( Site 0120)","city":"Beijing","state":"Beijing Municipality","zip":"100036","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"The Second Hospital Affiliated to AMU ( Site 0119)","city":"Chongqing","state":"Chongqing Municipality","zip":"400037","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"First Affiliated Hospital of The Third Military Medical University ( Site 0118)","city":"Chongqing","state":"Chongqing Municipality","zip":"400038","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Fujian Provincial Cancer Hospital ( Site 0102)","city":"Fuzhou","state":"Fujian","zip":"350014","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"facility":"Southern Medical University Nanfang Hospital ( Site 0121)","city":"Guangzhou","state":"Guangdong","zip":"510515","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"The Third Affiliated Hospital of Harbin Medical University ( Site 0100)","city":"Harbin","state":"Heilongjiang","zip":"150081","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Henan Cancer Hospital ( Site 0112)","city":"Zhengzhou","state":"Henan","zip":"450008","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Wuhan Union Hospital ( Site 0123)","city":"Wuhan","state":"Hubei","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Hubei Cancer Hospital ( Site 0122)","city":"Wuhan","state":"Hubei","zip":"430079","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Zhongshan Hospital Fudan University ( Site 0103)","city":"Shanghai","state":"Hunan","zip":"200032","country":"China"},{"facility":"Jilin Cancer Hospital ( Site 0115)","city":"Changchun","state":"Jilin","zip":"130103","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Shanghai Pulmonary Hospital ( Site 0101)","city":"Shanghai","state":"Shanghai Municipality","zip":"200443","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Tianjin Medical University Cancer Institute & Hospital ( Site 0111)","city":"Tianjin","state":"Tianjin Municipality","zip":"300060","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110)","city":"Urumuqi","state":"Xinjiang","zip":"830000","country":"China"},{"facility":"The First Affiliated Hospital Zhejiang University ( Site 0109)","city":"Hangzhou","state":"Zhejiang","zip":"310003","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Zhejiang Cancer Hospital ( Site 0113)","city":"Hangzhou","state":"Zhejiang","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"The First Affiliated Hospital of Wenzhou Medical University ( Site 0124)","city":"Wenzhou","state":"Zhejiang","zip":"325000","country":"China","geoPoint":{"lat":27.99942,"lon":120.66682}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://www.merckclinicaltrials.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"201 Chinese participants were randomized and received treatment as a part of global study \\[NCT03829319; n=761\\] or to the extension portion.\n\nNo participants from China were randomized to Part 1.","groups":[{"id":"FG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily."},{"id":"FG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"100"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"100"}]}],"dropWithdraws":[{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"33"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"67"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily."},{"id":"BG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"201"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.0","spread":"8.6"},{"groupId":"BG001","value":"60.9","spread":"8.2"},{"groupId":"BG002","value":"59.9","spread":"8.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"49"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"152"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"201"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"201"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Randomization of participants in the study was stratified by an ECOG Performance Status of 0 (Fully active, able to carry on all pre-disease performance without restriction) or 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"ECOG = 0","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"41"}]}]},{"title":"ECOG = 1","categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"160"}]}]}]},{"title":"Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline","description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Randomization of participants in the study was stratified by PD-L1 tumor proportion score (TPS) at baseline (\\< 50% or ≥ 50%). Higher percentages of PD-L1 TPS staining correspond to higher positivity of PD-L1 on a tumor.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"TPS = < 50%","categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"158"}]}]},{"title":"TPS = ≥ 50%","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"42"}]}]},{"title":"Not Evaluable","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Geographic Region","description":"Randomization of participants in this study was stratified by geographic region of the enrolling site (East Asia or non-East Asia).","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"East Asia","categories":[{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"201"}]}]},{"title":"Non-East Asia","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 is presented.","populationDescription":"All Chinese participants who were randomized to the global study (NCT03829319) or to the extension portion that were evaluable for response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 43 months","groups":[{"id":"OG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily."},{"id":"OG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","lowerLimit":"12.2","upperLimit":"19.6"},{"groupId":"OG001","value":"9.2","lowerLimit":"8.2","upperLimit":"12.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Based on Cox regression model with Efron's method of tie handling with treatment as a covariate","nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.48","ciUpperLimit":"0.97"}]},{"type":"PRIMARY","title":"Part 2: Overall Survival (OS)","description":"OS is defined as the time from randomization to the time of death from any cause. OS is presented.","populationDescription":"All Chinese participants who were randomized to the global study (NCT03829319) or to the extension portion that were evaluable for response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 43 months","groups":[{"id":"OG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily."},{"id":"OG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","lowerLimit":"22.2","upperLimit":"35.0"},{"groupId":"OG001","value":"22.0","lowerLimit":"16.6","upperLimit":"24.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Based on Cox regression model with Efron's method of tie handling with treatment as a covariate","nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"1.12"}]},{"type":"SECONDARY","title":"Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR as assessed per modified RECIST 1.1 will be presented.","populationDescription":"All Chinese participants who were randomized to the global study (NCT03829319) or to the extension portion that were evaluable for response.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Up to approximately 57 months","groups":[{"id":"OG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily."},{"id":"OG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","lowerLimit":"60.4","upperLimit":"79.0"},{"groupId":"OG001","value":"59.0","lowerLimit":"48.7","upperLimit":"68.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparision based on unstratified Miettinen \\& Nurminen method","nonInferiorityType":"OTHER","paramType":"Percent Difference","paramValue":"11.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.0","ciUpperLimit":"24.2"}]},{"type":"SECONDARY","title":"Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. DOR as assessed per modified RECIST 1.1 will be presented.","populationDescription":"All Chinese participants who were randomized to the global study (NCT03829319) or to the extension portion that were evaluable for response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"Up to approximately 57 months","groups":[{"id":"OG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily."},{"id":"OG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"51"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","lowerLimit":"12.6","upperLimit":"23.6"},{"groupId":"OG001","value":"12.5","lowerLimit":"6.7","upperLimit":"27.5"}]}]}]},{"type":"SECONDARY","title":"Part 2: Number of Participants Who Experienced an Adverse Event (AE)","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one of more adverse events during Part 2 of this study were presented.","populationDescription":"All Chinese participants who were randomized to the global study (NCT03829319) or to the extension portion who received at least one dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 42 months","groups":[{"id":"OG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily."},{"id":"OG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"100"}]}]}]},{"type":"SECONDARY","title":"Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment during Part 2 of this study were presented.","populationDescription":"All Chinese participants who were randomized to the global study (NCT03829319) or to the extension portion who received at least one dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 42 months","groups":[{"id":"OG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily."},{"id":"OG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"21"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to approximately 42 months for first course and up to approximately 57 months for second course. All-cause mortality (ACM): Up to approximately 57 months for first and second course.","description":"All-cause mortality includes all randomized participants. Safety includes participants who received ≥1 dose of study treatment. Per protocol, disease progression was not considered an AE, unless related to study treatment. Thus, MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to study treatment were excluded as AEs","eventGroups":[{"id":"EG000","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily.","deathsNumAffected":65,"deathsNumAtRisk":101,"seriousNumAffected":67,"seriousNumAtRisk":101,"otherNumAffected":100,"otherNumAtRisk":101},{"id":"EG001","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily.","deathsNumAffected":67,"deathsNumAtRisk":100,"seriousNumAffected":53,"seriousNumAtRisk":100,"otherNumAffected":99,"otherNumAtRisk":100},{"id":"EG002","title":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo(Second Course)","description":"Qualified participants who completed the first course of pembrolizumab plus chemotherapy plus lenvatinib for up to 35 cycles (up to 2 years), but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q2W for up to \\~1 year. Participants previously receiving placebo could continue receiving placebo at investigator's discretion.","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":1,"seriousNumAtRisk":2,"otherNumAffected":1,"otherNumAtRisk":2}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":101},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Aplastic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Myelosuppression","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Immune-mediated myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Adrenal haematoma","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Gastric mucosal lesion","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Gastrointestinal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Immune-mediated pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":101},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":100},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":2}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Tuberculous pleurisy","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Tracheal haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":101},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":101},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":101},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Osteonecrosis of jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Basal ganglia infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Encephalitis autoimmune","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Immune-mediated nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Renal tubular injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hydrothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":101},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pulmonary artery thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Dermatitis herpetiformis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Ulcerative keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":266,"numAffected":84,"numAtRisk":101},{"groupId":"EG001","numEvents":224,"numAffected":82,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":101},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":101},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":25,"numAtRisk":101},{"groupId":"EG001","numEvents":17,"numAffected":14,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":101},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":101},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":26,"numAtRisk":101},{"groupId":"EG001","numEvents":55,"numAffected":41,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":19,"numAtRisk":101},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":101},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":91,"numAffected":34,"numAtRisk":101},{"groupId":"EG001","numEvents":67,"numAffected":35,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":101},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":10,"numAtRisk":101},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":23,"numAtRisk":101},{"groupId":"EG001","numEvents":24,"numAffected":19,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":15,"numAtRisk":101},{"groupId":"EG001","numEvents":19,"numAffected":10,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":101},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":101},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":23,"numAtRisk":101},{"groupId":"EG001","numEvents":27,"numAffected":17,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":101},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":101},{"groupId":"EG001","numEvents":26,"numAffected":12,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":17,"numAtRisk":101},{"groupId":"EG001","numEvents":21,"numAffected":17,"numAtRisk":100},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":2}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":101},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":101},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":16,"numAtRisk":101},{"groupId":"EG001","numEvents":18,"numAffected":13,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":101},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":191,"numAffected":63,"numAtRisk":101},{"groupId":"EG001","numEvents":183,"numAffected":58,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":21,"numAtRisk":101},{"groupId":"EG001","numEvents":31,"numAffected":18,"numAtRisk":100},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":2}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":226,"numAffected":67,"numAtRisk":101},{"groupId":"EG001","numEvents":188,"numAffected":61,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":101},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":22,"numAtRisk":101},{"groupId":"EG001","numEvents":29,"numAffected":18,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":14,"numAtRisk":101},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":28,"numAtRisk":101},{"groupId":"EG001","numEvents":45,"numAffected":22,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":16,"numAtRisk":101},{"groupId":"EG001","numEvents":16,"numAffected":10,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":14,"numAtRisk":101},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":101},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Fibrin D dimer increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":101},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":37,"numAtRisk":101},{"groupId":"EG001","numEvents":51,"numAffected":34,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":14,"numAtRisk":101},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":21,"numAtRisk":101},{"groupId":"EG001","numEvents":28,"numAffected":12,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":401,"numAffected":83,"numAtRisk":101},{"groupId":"EG001","numEvents":326,"numAffected":74,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":248,"numAffected":65,"numAtRisk":101},{"groupId":"EG001","numEvents":140,"numAffected":47,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Urinary occult blood positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":2}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":29,"numAtRisk":101},{"groupId":"EG001","numEvents":16,"numAffected":14,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":20,"numAtRisk":101},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":366,"numAffected":78,"numAtRisk":101},{"groupId":"EG001","numEvents":293,"numAffected":70,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":89,"numAffected":38,"numAtRisk":101},{"groupId":"EG001","numEvents":78,"numAffected":44,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":26,"numAtRisk":101},{"groupId":"EG001","numEvents":43,"numAffected":16,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":11,"numAtRisk":101},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypermagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":101},{"groupId":"EG001","numEvents":7,"numAffected":2,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":73,"numAffected":12,"numAtRisk":101},{"groupId":"EG001","numEvents":46,"numAffected":13,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":15,"numAtRisk":101},{"groupId":"EG001","numEvents":35,"numAffected":13,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":34,"numAtRisk":101},{"groupId":"EG001","numEvents":62,"numAffected":25,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":14,"numAtRisk":101},{"groupId":"EG001","numEvents":19,"numAffected":7,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":9,"numAtRisk":101},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":19,"numAtRisk":101},{"groupId":"EG001","numEvents":25,"numAffected":18,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":25,"numAtRisk":101},{"groupId":"EG001","numEvents":26,"numAffected":15,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":12,"numAtRisk":101},{"groupId":"EG001","numEvents":11,"numAffected":5,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":101},{"groupId":"EG001","numEvents":20,"numAffected":9,"numAtRisk":100},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":2}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":101},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":101},{"groupId":"EG001","numEvents":18,"numAffected":14,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":8,"numAtRisk":101},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":101},{"groupId":"EG001","numEvents":21,"numAffected":13,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":101},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":22,"numAffected":13,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Albuminuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":8,"numAtRisk":101},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":75,"numAffected":33,"numAtRisk":101},{"groupId":"EG001","numEvents":35,"numAffected":23,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":17,"numAtRisk":101},{"groupId":"EG001","numEvents":18,"numAffected":14,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":101},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":12,"numAtRisk":101},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":101},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":101},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":101},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":101},{"groupId":"EG001","numEvents":18,"numAffected":10,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":19,"numAtRisk":101},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":100},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":34,"numAtRisk":101},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":100},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":2}]},{"term":"Degenerative aortic valve disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":101},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":2}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@msd.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2023-10-27","uploadDate":"2025-08-20T15:22","filename":"Prot_SAP_002.pdf","size":1548698}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-08-23","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"C565324","term":"Parkinson Disease 4, Autosomal Dominant Lewy Body"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D002945","term":"Cisplatin"},{"id":"D000068437","term":"Pemetrexed"},{"id":"C531958","term":"lenvatinib"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}